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As a result of improvements in medical care and
increasing survival, atherosclerotic cardiovascular
disease is now the leading cause of death in pa-
tients with spinal cord injury (SCI).1,2 Coronary
heart disease is more prevalent and occurs earlier
in patients with SCI than in the able-bodied pop-
ulation.3,4 As a consequence of changes in body
composition and reduction in physical activity,
Circulating Levels of Markers of Inflammation
and Endothelial Activation are Increased in
Men with Chronic Spinal Cord Injury
Tzung-Dau Wang,1 Yen-Ho Wang,2 Tien-Shang Huang,1* Ta-Chen Su,3 Shin-Liang Pan,2
Ssu-Yuan Chen2
Background/Purpose: Accelerated atherogenesis is often seen in individuals with chronic spinal cord injury
(SCI). However, the mechanisms contributing to this phenomenon remain unclear. This study aimed to
evaluate whether SCI per se is associated with a low-grade chronic inflammatory state and endothelial 
activation, both of which are well-documented prerequisites for atherogenesis.
Methods: Serum levels of markers of inflammation (C-reactive protein [CRP], interleukin-6, and soluble
CD40 ligand) and endothelial activation (endothelin-1, soluble intercellular adhesion molecule-1, and
soluble vascular cell adhesion molecule-1 [sVCAM-1]) were measured in SCI patients with CRP levels
< 10 mg/L and with no evidence of active infection. Sixty-two men with traumatic neurologically complete
SCI (20 tetraplegics and 42 paraplegics) and 29 age-matched male controls were enrolled.
Results: Compared with able-bodied controls, subjects with SCI had a significantly lower body mass index
(BMI) (−7%) and significantly lower serum levels of albumin (−10%), creatinine (−20%), low-density
lipoprotein cholesterol (−10%), and high-density lipoprotein (HDL) cholesterol (−25%), and showed a
trend toward higher fasting insulin levels. Irrespective of injury level and duration, subjects with SCI had
significantly higher serum levels, compared to able-bodied controls, of CRP (mean, 4.0 ± 2.7 mg/L vs.
1.4 ± 1.1 mg/L), interleukin-6 (median, 2.5 pg/mL vs. 0.4 pg/mL; range, 1.5–3.6 pg/mL vs. 0.2–0.5 pg/mL),
endothelin-1 (mean, 1.3 ± 0.4 pg/mL vs. 0.9 ± 0.3 pg/mL), and sVCAM-1 (mean, 1170 ± 318 ng/mL vs. 542 ±
318 ng/mL). The serum levels of all four factors correlated negatively with levels of serum albumin, creatinine
and HDL cholesterol, but not with BMI or fasting insulin levels. In multivariate analyses, SCI was the only
factor that was independently associated with increased serum levels of CRP, interleukin-6, endothelin-1
and sVCAM-1 after adjustment for confounding factors such as serum albumin and creatinine levels and
parameters of dyslipidemia and insulin resistance.
Conclusion: In this study, we have, for the first time, demonstrated that SCI per se is associated with a low-
grade chronic inflammatory state and endothelial activation, which may partly explain the increased
atherogenic risk in patients with long-standing SCI. [J Formos Med Assoc 2007;106(11):919–928]
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ORIGINAL ARTICLE
individuals with SCI often show metabolic alter-
ations, such as insulin resistance and dyslipidemia,
which may increase the risk of coronary heart
disease.1 However, whether other mechanisms
contribute to the accelerated atherogenesis seen
in patients with SCI is not clear.
Recently, atherosclerosis has been viewed as 
a dynamic and progressive disease arising from a
combination of endothelial activation and low-
grade inflammation.5–7 Endothelial cells provide
the barrier between the circulation and the extra-
vascular space. Endothelial activation and endo-
thelial cell-leukocyte interactions are a necessary
prerequisite for initiation of inflammatory pro-
cesses that predispose to atherogenesis. Moreover,
inflammatory mediators appear to play a funda-
mental role in the initiation, progression, and
eventual rupture of atherosclerotic plaques. Mea-
surement of markers of inflammation and en-
dothelial activation may therefore be useful by
providing a mechanistic explanation for the in-
creased cardiovascular risk in certain patient
populations.
Serologic levels of inflammatory markers, such
as C-reactive protein (CRP) and interleukin-6,
have been shown to be significantly elevated in
patients with SCI.8–10 However, the SCI patients
included in those studies had either manifest or
occult evidence of active infection, as CRP levels
were greater than 10 mg/L, the commonly assigned
cut-off value for CRP.9–12 This degree of CRP ele-
vation indicates the presence of acute infection
or inflammation,12 which is different from the
chronic low-grade inflammation associated with
atherosclerosis.6 In order to evaluate whether
SCI per se is associated with a low-grade chronic
inflammatory state and endothelial activation,
we measured serum levels of markers of inflam-
mation (CRP, interleukin-6, and soluble CD40
ligand) and endothelial activation (endothelin-1,
soluble intercellular adhesion molecule-1 [sICAM-
1], and soluble vascular cell adhesion molecule-1
[sVCAM-1]) in SCI patients with CRP levels less
than 10 mg/L and with no evidence of active in-
fection. We also investigated possible correlations
between these serum markers and various factors,
such as injury level, duration of injury, body mass
index (BMI), serum albumin and creatinine levels,
and metabolic parameters of dyslipidemia and
insulin resistance.
Methods
Participants
Eighty-nine men with traumatic SCI were recruited
from the SCI clinic of National Taiwan University
Hospital. Their SCIs were neurologically com-
plete, as defined by the American Spinal Injury
Association.13 The injury levels were from C3 to
L1. Those with injury levels at or above C8 were
classified as tetraplegics and the others as para-
plegics. To avoid the confounding effect of infec-
tion, 27 subjects with evidence of active infection
or CRP levels ≥ 10 mg/L were excluded. A total of
62 SCI subjects (42 with paraplegia and 20 with
tetraplegia) were included in this study. These
subjects had been injured at a mean age of 28.0 ±
9.7 years (range, 16.2–59.1 years), and the mean
duration of injury was 11.8 ± 7.0 years (range,
1.2–27.7 years). The control group consisted of
29 age-matched healthy men. No participants in
either the control or SCI groups had known dia-
betes or endocrine disorders. Except for a few pa-
tients who were taking stool softeners (magnesium
oxide) or low-dose antispastic agents (baclofen),
none were taking drugs regularly. All participants
voluntarily agreed to participate in this study
and all gave written informed consent. The study
was approved by the research ethics committee
of National Taiwan University Hospital.
Laboratory analyses
Blood samples were taken from all participants
between 8:00 and 9:00 am after overnight fasting,
and serum was prepared and stored frozen at 
−70°C until assayed. Levels of total cholesterol,
total triglycerides, low-density lipoprotein (LDL)
cholesterol, and high-density lipoprotein (HDL)
cholesterol were assayed by routine laboratory
techniques and the methods used in the Lipid
Research Clinics, as reported previously.14 If plasma
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triglycerides were ≥ 400 mg/dL, LDL cholesterol
was assessed by a direct method.14 High-sensitivity
CRP levels were measured by rate nephelometry
(Dade Behring, Newark, DE, USA). Serum levels
of insulin, soluble CD40 ligand, endothelin-1,
sICAM-1, and sVCAM-1 were determined in du-
plicate using commercially available ELISA kits
(insulin, BIOSOURCE, Camarillo, CA, USA; sol-
uble CD40 ligand, endothelin-1, sICAM-1, and
sVCAM-1, R&D Systems, Minneapolis, MN, USA).
The marker of insulin resistance, the homeostasis
model assessment (HOMA) index, is defined as
the fasting plasma insulin level (µU/mL) × fasting
glucose level (mmol/L)/22.5. Routine clinical
chemical analyses were performed by standard
methods subject to strict quality control. The co-
efficients of variation were < 5% for all types of
measurement.15
Statistical analyses
Statistical analyses were performed using SPSS
version 11.0 (SPSS Inc., Chicago, IL, USA). Data
were examined for normality before analysis, and
the distributions of levels of interleukin-6, soluble
CD40 ligand, fasting glucose, insulin and triglyc-
erides, and the HOMA index were found to be
positively skewed. The data were therefore ana-
lyzed by nonparametric methods to avoid assump-
tions about the distribution of the measured
variables. Differences in demographic character-
istics and various biochemical markers between
subjects with SCI and able-bodied controls were
compared using the Mann–Whitney U test. Differ-
ences in the above variables between paraplegics
and tetraplegics and between those with injury 
at T6 and above and those with injury at T7 and
below were compared using either the Mann–
Whitney U test (duration of injury) or one-way
analysis of variance (ANOVA) with post hoc
Bonferroni tests (all other variables). Associations
between different variables were assessed using the
Spearman rank correlation test. Multivariate regres-
sion analysis was used to test the independent asso-
ciation between various serum markers and SCI in
the whole study population using a forward step-
wise linear regression model with age, BMI, serum
levels of albumin, creatinine, glucose and insulin,
lipid profiles, and the HOMA index as covariates.
The distribution of continuous variables in groups
was expressed as mean± standard deviation or me-
dian (interquartile range) as appropriate. Statistical
significance was set at p < 0.05.
Results
The characteristics of the 62 subjects with SCI and
the 29 able-bodied controls are listed in Table 1.
Compared to able-bodied controls, subjects with
SCI had a significantly lower body weight, BMI,
and serum levels of albumin and creatinine. The
difference in serum creatinine levels (−20%) be-
tween SCI subjects and able-bodied controls was
greater than those for body weight (−8%), BMI
(−7%), and serum albumin levels (−10%), prob-
ably due to a greater reduction in lean muscle
mass in SCI subjects or differences in renal func-
tion status. As regards the metabolic parameters
of dyslipidemia and insulin resistance, subjects
with SCI had significantly lower HDL and LDL
cholesterol levels, a higher total cholesterol/HDL
cholesterol ratio, and a trend toward higher in-
sulin levels than able-bodied controls. Although
all participants had CRP levels < 10 mg/L and no
evidence of active infection, subjects with SCI
had significantly higher serum levels of CRP, 
interleukin-6, endothelin-1 and sVCAM-1 than
able-bodied controls. There were no significant
differences between paraplegics and tetraplegics
with regard to injury duration, demographic char-
acteristics, parameters of dyslipidemia and insulin
resistance, and markers of inflammation and en-
dothelial activation, except that tetraplegic sub-
jects had significantly lower serum albumin and
marginally lower sICAM-1 levels than paraplegic
subjects. SCI subjects with injury at T6 and above
had significantly lower albumin levels than those
with injury at T7 and below, but there were no
significant differences in any of the other param-
eters. There were no significant relations between
injury duration and markers of inflammation and
endothelial activation (data not shown).
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The associations between markers of inflam-
mation and endothelial activation in all study
participants are shown in Table 2. CRP levels were
significantly correlated with all other parameters,
most notably interleukin-6. Soluble CD40 lig-
and levels were only correlated with CRP levels.
Endothelin-1 levels were significantly correlated
with levels of CRP, interleukin-6 and sVCAM-1,
but not sICAM-1, whereas sICAM-1 levels were
correlated with levels of CRP and interleukin-6,
but not with other markers of endothelial activa-
tion (endothelin-1 and sVCAM-1).
The associations between the above markers
and age, BMI, serum albumin and creatinine lev-
els, and parameters of dyslipidemia and insulin
resistance in all study participants are shown 
in Table 3. Higher CRP levels were significantly
associated with lower levels of albumin and creati-
nine, higher fasting glucose and insulin levels, and
lower HDL cholesterol levels, but not with BMI.
Interleukin-6 had a similar correlation pattern to
CRP. Both endothelin-1 and sVCAM-1 levels were
correlated positively with age and negatively with
serum levels of albumin, creatinine and HDL cho-
lesterol, but not with BMI or fasting glucose and
insulin levels. Higher sICAM-1 levels were signi-
ficantly associated with higher BMI and higher
fasting insulin and triglyceride levels.
To determine whether there were independent
associations between SCI and increased serum
levels of CRP, interleukin-6, endothelin-1 and
sVCAM-1, we performed stepwise multiple linear
regression analyses including each single serum
marker as the dependent variable and age, the
Inflammation and endothelial activation in SCI
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Table 2. Spearman rank correlation coefficients between levels of markers of inflammation and endothelial
activation in all study participants (n = 91)
Interleukin-6 Soluble CD40 ligand Endothelin-1 sICAM-1 sVCAM-1
CRP 0.668* 0.239† 0.216† 0.398* 0.373*
Interleukin-6 — 0.101 0.458* 0.324‡ 0.585*
Soluble CD40 ligand — — 0.092 0.171 −0.025
Endothelin-1 — — — 0.065 0.332‡
sICAM-1 — — — — 0.205
*p<0.001; †p<0.05; ‡p<0.01. sICAM-1 = soluble intercellular adhesion molecule-1; sVCAM-1 = soluble vascular cell adhesion molecule-1;
CRP = C-reactive protein.
Table 3. Spearman rank correlation coefficients between levels of markers of inflammation and endothelial
activation and biochemical and anthropometric variables in all study participants (n = 91)
CRP Interleukin-6 Soluble CD40 ligand Endothelin-1 sICAM-1 sVCAM-1
Age 0.067 0.048 0.024 0.308* 0.079 0.281*
BMI 0.097 −0.065 0.211† −0.145 0.237† −0.127
Albumin −0.366‡ −0.529‡ −0.028 −0.418‡ 0.044 −0.562‡
Creatinine −0.439‡ −0.450‡ −0.096 −0.235† −0.097 −0.549‡
Fasting glucose 0.212† −0.011 0.044 0.036 −0.078 −0.105
Fasting insulin 0.290* 0.212† 0.121 −0.012 0.268† 0.182
HOMA index 0.315* 0.193 0.147 −0.004 0.253† 0.154
Total cholesterol −0.131 −0.131 0.192 0.019 0.063 −0.145
Triglycerides 0.203 0.143 0.310* 0.201 0.286* 0.064
LDL cholesterol −0.090 −0.166 0.211† −0.075 0.077 −0.136
HDL cholesterol −0.519‡ −0.574‡ −0.113 −0.326* −0.125 −0.491‡
*p<0.01; †p<0.05; ‡p<0.001. CRP = C-reactive protein; sICAM-1 = soluble intercellular adhesion molecule-1; sVCAM-1 = soluble vascular
cell adhesion molecule-1; BMI = body mass index; HOMA = homeostasis model assessment; LDL = low-density lipoprotein; HDL = high-
density lipoprotein.
presence or absence of SCI, BMI, serum albumin
and creatinine levels, and parameters of dyslipide-
mia and insulin resistance as covariates (Table 4).
Multivariate analyses showed that SCI was the
only factor that was independently associated
with increased serum levels of CRP, interleukin-6,
endothelin-1 and sVCAM-1. Serum creatinine lev-
els were independently and negatively associated
with levels of CRP, endothelin-1 and sVCAM-1,
whereas HDL cholesterol levels were negatively
correlated with CRP.
Discussion
In this study, we have, for the first time, shown
that in men with chronic SCI (duration of injury
> 1 year) and with no clinical or serologic evi-
dence of active infection, serum levels of CRP, 
interleukin-6, endothelin-1 and sVCAM-1 are sig-
nificantly increased, irrespective of injury dura-
tion and injury levels, compared to able-bodied
controls. Although SCI subjects usually have a 
reduced lean muscle mass (as manifested by 
decreased creatinine levels) and features of the 
insulin-resistant metabolic syndrome (lower HDL
cholesterol levels and hyperinsulinemia),16 the
positive associations between SCI and serum 
levels of CRP, interleukin-6, endothelin-1 and
sVCAM-1 remained statistically significant after
adjustment for all these confounding factors.
These findings indicate that SCI per se is associ-
ated with a low-grade chronic inflammatory state
and endothelial activation, which may partly ex-
plain the increased atherogenic risk in patients
with long-standing SCI.
The inflammatory etiology of atherosclerosis
has prompted a search for biomarkers of inflam-
mation that predict risk for coronary heart dis-
ease and its sequelae. The marker of inflammation
that has received the most attention recently as a
potential marker of atherosclerotic risk is CRP.
CRP, an acute-phase protein and a member of the
pentraxin family, is produced by hepatocytes and
possibly smooth muscle cells and monocytes/
macrophages in response to inflammatory cyto-
kines, including interleukin-6.5 CRP levels increase
several hundred-fold in response to acute injury,
infection or other inflammatory stimuli. Tradi-
tionally, CRP has been used to monitor infectious
and rheumatologic diseases, with a commonly
assigned cut-off value of < 10 mg/L.12 As a conse-
quence of recurrent infections from pressure ulcers
and urinary tract infections, which are frequently
T.D. Wang, et al
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Table 4. Multivariate forward stepwise linear regression analysis of variables significantly related to levels of
CRP, interleukin-6, endothelin-1, or sVCAM-1 in all study participants (n = 91)
Standardized β coefficient p
Dependent variable: CRP (model r = 0.549, p < 0.001)
HDL cholesterol −0.290 0.006
Creatinine −0.182 0.021
Spinal cord injury 0.199 0.025
Dependent variable: interleukin-6 (model r = 0.552, p < 0.001)
Spinal cord injury 0.552 < 0.001
Dependent variable: endothelin-1 (model r = 0.635, p < 0.001)
Spinal cord injury 0.586 < 0.001
Age 0.340 < 0.001
Creatinine −0.289 0.003
Dependent variable: sVCAM-1 (model r = 0.699, p < 0.001)
Spinal cord injury 0.600 < 0.001
Creatinine −0.178 0.004
CRP = C-reactive protein; HDL = high-density lipoprotein; sVCAM-1 = soluble vascular cell adhesion molecule-1.
encountered in patients with long-term SCI, sev-
eral previous studies have shown that serologic
CRP levels are markedly elevated (> 10 mg/L) in
both symptomatic and asymptomatic patients
with SCI compared with able-bodied individu-
als.9–11 Although asymptomatic SCI patients were
also included in these studies, the markedly ele-
vated CRP levels indicate that they probably had
occult infections. Likewise, recently published re-
commendations regarding the application of CRP
to clinical practice suggest that, if CRP level is
≥ 10 mg/L, the test should be repeated and the
patient examined for sources of infection or 
inflammation.12
It is well recognized that CRP levels measured
to assess atherosclerotic risk caused by chronic
low-grade inflammation are much lower than
those measured in acute inflammation.12 CRP
measurements improve the accuracy in coronary
risk assessment over and above the use of con-
ventional risk factors.17,18 The cut-off points for
CRP levels recommended for coronary risk as-
sessment are < 1.0 mg/L (low risk), 1.0–3.0 mg/L
(average risk), and > 3.0 mg/L (high risk). The
present study is the first to deliberately exclude
the confounding effect of infection on CRP levels
in patients with long-term SCI by including only
asymptomatic patients with CRP levels < 10 mg/L.
We clearly demonstrated that the mean CRP levels
in patients with long-term SCI were in the high-
risk category. The observed concomitant elevation
of circulating interleukin-6 levels is consistent with
the fact that interleukin-6 is the primary cytokine
mediator of CRP production.6 Despite increases
in the levels of both CRP and interleukin-6 indi-
cating that patients with long-term SCI are asso-
ciated with chronic low-grade inflammation, it is
noteworthy that serum levels of soluble CD40
ligand did not differ between SCI patients and
able-bodied individuals. Soluble CD40 ligand is
a proinflammatory and prothrombotic molecule,
which plays a role in the pathogenesis of ath-
erosclerosis and acute coronary syndromes.19,20
Recent studies have shown that circulating solu-
ble CD40 ligand is largely derived from activated
platelets.19 The lack of a difference in soluble
CD40 ligand levels between SCI patients and able-
bodied individuals might therefore suggest that
SCI is not associated with clinically significant
platelet activation.
The etiology of the increases in CRP and 
interleukin-6 levels in SCI patients free of coexist-
ing infections appears to be multifactorial. First,
in non-disabled people, higher circulating levels
of CRP and interleukin-6 are significantly associ-
ated with components of the insulin-resistant
metabolic syndrome, which is characterized by
low levels of HDL cholesterol, elevated levels of
fasting glucose, insulin and triglycerides, and ab-
dominal obesity.15,21 As a consequence of the re-
duction in physical activity and a loss of muscle
mass due to atrophy by paralysis below the level
of injury, patients with long-term SCI often have
greater adiposity for a given BMI and, therefore,
are more insulin-resistant than able-bodied in-
dividuals.1,22 In this study, we showed that SCI
patients had significantly lower HDL cholesterol
and creatinine levels than able-bodied controls.
Moreover, CRP and interleukin-6 levels correlated
negatively with HDL cholesterol and creatinine
levels in the study participants. This finding sug-
gests that both body composition changes and the
metabolic syndrome contribute to the increased
CRP and interleukin-6 levels seen in SCI patients.
Second, several recent studies have shown that
sympathetic overactivity is associated with elevated
CRP levels and subclinical low-grade inflamma-
tion.23,24 In patients with long-term SCI, somato-
sensory and visceral stimuli below the level of the
lesion can give rise to exaggerated sympathetic
activity and marked norepinephrine spillover.1
This may partly explain the independent associa-
tion between elevated CRP levels and SCI after
excluding the possible confounding effects of
various metabolic parameters. However, despite
sympathetic overactivity being primarily observed
in SCI patients with an injury level above T7,25
we found no differences in circulating CRP and
interleukin-6 levels between SCI patients with an
injury level above or below T7. Third, although SCI
patients with CRP levels ≥ 10 mg/L were excluded
in this study, it is still possible that very subtle 
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infections and bladder management techniques
might influence CRP and interleukin-6 levels in
these long-term SCI patients.
In addition to subclinical inflammation, we
have, for the first time, showed that chronic 
SCI is associated with serologic evidence of
endothelial activation, as manifested by signifi-
cant increases in endothelin-1 and sVCAM-1 
levels and a marginal increase in sICAM-1 levels.
Endothelin-1 is a potent vasoconstrictor peptide
secreted by endothelial cells in response to in-
sulin, catecholamines, and other agonists, and
has been shown to play a seminal role in the
atherogenic process by enhancing mitogenesis
and inducing extracellular matrix formation.26,27
It is of interest that the serum endothelin-1 levels
in our long-term SCI patients were similar to
those in patients with insulin-resistant metabolic
syndrome, which is known to be associated with
increased endothelin-1 levels.28,29 Likewise, serum
endothelin-1 levels were shown to correlate neg-
atively with serum HDL cholesterol levels in the
study population, suggesting that the increased
endothelin-1 levels were partly attributable to
the metabolic syndrome.
Leukocyte adhesion to the endothelial sur-
face, resulting from the expression of cell surface
adhesion molecules, is a key factor in the athero-
genic process. Two molecules of the transmem-
brane immunoglobulin superfamily, ICAM-1 and
VCAM-1, are prototypic cell adhesion molecules
and serve as endothelial ligands for the integrins
expressed on both leukocytes and platelets and
mediate tight attachment to the endothelium.5
Soluble forms of both adhesion molecules have
been detected in human plasma and serum and
their levels have been found to be elevated in
various inflammatory disorders.5,30 In this study,
we demonstrated that patients with chronic SCI
had significantly elevated sVCAM-1 levels and
mildly elevated sICAM-1 levels. This discordance
in the elevation of circulating sVCAM-1 and
sICAM-1 levels in SCI patients is intriguing. There
are several plausible explanations for this finding,
other than it being a chance finding. First, a recent
study demonstrated that circulating sVCAM-1
levels, but not sICAM-1 levels, are elevated differ-
entially in various stages of coronary atheroscle-
rosis.30 This finding suggests that sVCAM-1 is more
sensitive in reflecting the activity and stability of
atherosclerotic plaques. Because the sample size
in the present study was limited, it is possible
that only differences in the more sensitive mark-
ers were identified. Second, it is of interest that
sVCAM-1 and sICAM-1 levels correlated with dif-
ferent components of the metabolic syndrome 
in this study population: sVCAM-1 levels corre-
lated significantly with HDL cholesterol levels,
whereas sICAM-1 levels correlated with insulin
and triglyceride levels. A similar finding was found
in able-bodied individuals of South Asian origin.31
Although low HDL cholesterol and high triglyc-
eride and insulin levels are all components of the
metabolic syndrome,1 only low HDL cholesterol
was found in our SCI patients. Thus, the contribu-
tion of the metabolic syndrome to levels of mark-
ers of endothelial activation in chronic SCI was
more evident from the change in sVCAM-1 levels
than that in sICAM-1 levels. Third, it has been
shown that endothelin-1, by activating nuclear
factor κB, can increase the expression of cardiac
VCAM-1, but not that of ICAM-1, in hypertensive
rats.32 Consistent with this observation, we found
that sVCAM-1 levels correlated significantly with
endothelin-1 levels, which might also contribute
to the more significant increase in sVCAM-1 levels
than in sICAM-1 levels in SCI patients.
There were several limitations in this study.
First, the serum markers were measured at a sin-
gle time point for each patient, so we cannot ex-
clude variability in the levels of these markers
with time. However, a previous study showed that
in about 90% of cases, two independent CRP
measurements taken 3 months apart were within
one quartile of each other.12 Second, we used BMI
as a surrogate marker for adiposity. However, BMI
does not distinguish the anatomic site of fat mass,
and subjects with paraplegia and tetraplegia have
different body compositions compared to each
other or to able-bodied individuals. Given that
the amount of fat mass has been shown to corre-
late with levels of markers of inflammation and
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endothelial activation,33 we may therefore have
underestimated the influence of body composi-
tion on these markers. To reduce the effect of this
limitation, we also included serum creatinine lev-
els, a surrogate marker of muscle mass,16 in addi-
tion to BMI, in the multivariate analysis model to
control for the confounding effect of body com-
position. Third, the case number in the present
study was relatively small. Hence, findings from
the present study need to be verified in further
larger-scale studies.
In conclusion, we have demonstrated that in-
dividuals with SCI have serologic evidence of
subclinical inflammation and endothelial activa-
tion and features of the metabolic syndrome and
changes in body composition. Given that accel-
erated atherogenesis is often seen in individuals
with chronic SCI, our findings suggest that 
subclinical inflammation and endothelial activa-
tion may serve as possible mechanisms linking
chronic SCI and atherogenic risk. Further studies
are needed to explore the relationships between
levels of serum markers of inflammation (CRP
and interleukin-6) and endothelial activation
(endothelin-1 and sVCAM-1) and parameters of
subclinical atherosclerosis (carotid intima-media
thickness, brachial artery vasoreactivity, and coro-
nary calcification) or the development of cardio-
vascular events in SCI subjects and to validate
the clinical utility of these markers.
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